1. Metabolic Enzyme/Protease Apoptosis
  2. Fatty Acid Synthase (FASN) Apoptosis Endogenous Metabolite
  3. Betulin

Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line.

For research use only. We do not sell to patients.

Betulin Chemical Structure

Betulin Chemical Structure

CAS No. : 473-98-3

Size Price Stock Quantity
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Betulin:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line.

IC50 & Target

IC50: 14.5 μM (SREBP, K562 cell), 74.1 μM (SREBP, HeLa cell), 17.1 μM (SREBP, GOTO cell)[1], 21.09 μM (SREBP, 181P cell), 20.62 μM (SREBP, HeLa cell)[2]

Cellular Effect
Cell Line Type Value Description References
518A2 EC50
> 30 μM
Compound: BN
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 27142753]
518A2 EC50
> 30 μM
Compound: 2
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 26547057]
518A2 EC50
28.8 μM
Compound: Betulin
Cytotoxicity against human 518A2 cells by SRB assay
Cytotoxicity against human 518A2 cells by SRB assay
[PMID: 26007303]
8505C EC50
> 30 μM
Compound: Betulin
Cytotoxicity against human 8505C cells by SRB assay
Cytotoxicity against human 8505C cells by SRB assay
[PMID: 26007303]
A2780 IC50
> 10 μM
Compound: 23
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
[PMID: 24467317]
A2780 EC50
> 30 μM
Compound: BN
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
A2780 EC50
> 30 μM
Compound: BN
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 27142753]
A2780 EC50
> 30 μM
Compound: 2
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 26547057]
A2780 EC50
29.3 μM
Compound: Betulin
Cytotoxicity against human A2780 cells by SRB assay
Cytotoxicity against human A2780 cells by SRB assay
[PMID: 26007303]
A2780 IC50
6.1 μM
Compound: 10
Cytotoxicity against human A2780 cells after 4 days by MTT assay
Cytotoxicity against human A2780 cells after 4 days by MTT assay
[PMID: 19702283]
A-375 EC50
> 30 μM
Compound: BN
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
A-375 IC50
28 μM
Compound: 1, BE, Betulin
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
[PMID: 26280921]
A549 IC50
> 10 μM
Compound: 23
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
[PMID: 24467317]
A549 IC50
> 200 μM
Compound: 2
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
[PMID: 19200744]
A549 EC50
> 30 μM
Compound: BN
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 27142753]
A549 EC50
> 30 μM
Compound: 2
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 26547057]
A549 IC50
> 316 μM
Compound: 13
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 15730243]
A549 IC50
> 316 μM
Compound: 13
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
[PMID: 15730243]
A549 IC50
18.15 μM
Compound: 1
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 28671831]
A549 EC50
20.6 μM
Compound: Betulin
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
[PMID: 26007303]
A549 IC50
3.8 μM
Compound: 1
Cytotoxicity against human A549 cells after 48 hrs
Cytotoxicity against human A549 cells after 48 hrs
[PMID: 19115839]
A549 IC50
3.8 μM
Compound: 2
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
[PMID: 19200744]
A549 IC50
3.8 μM
Compound: 2
Cytotoxicity against human A549 cells by resazurin reduction test
Cytotoxicity against human A549 cells by resazurin reduction test
[PMID: 19285391]
A549 IC50
59.73 μM
Compound: 1
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
[PMID: 31158746]
ADR5000 cell line IC50
56.5 μM
Compound: betulin
Cytotoxicity against human CEM/ADR5000 by XTT assay
Cytotoxicity against human CEM/ADR5000 by XTT assay
[PMID: 20527917]
B16 IC50
27.4 μM
Compound: 4
Growth inhibition of mouse B16 2F2 cells after 3 days
Growth inhibition of mouse B16 2F2 cells after 3 days
[PMID: 12027734]
B16 ED50
4.8 μM
Compound: 4
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
[PMID: 12027734]
Bcap37 IC50
25.5 μM
Compound: 1, BE, Betulin
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
[PMID: 26280921]
Bel-7402 IC50
> 10 μM
Compound: 23
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
[PMID: 24467317]
BGC-823 IC50
> 10 μM
Compound: 23
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
[PMID: 24467317]
BGC-823 IC50
> 20 μM
Compound: Betulin
Antiproliferative activity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31708185]
BV-2 IC50
> 10 μM
Compound: 23
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 24467317]
BXPC-3 GI50
9.3 μg/mL
Compound: Betulin
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
[PMID: 29303263]
BXPC-3 GI50
9.3 μg/mL
Compound: 1
Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay
Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay
[PMID: 24694263]
CAPAN-1 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
CCRF-CEM IC50
> 50 μM
Compound: 1
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay
[PMID: 27236068]
CCRF-CEM IC50
250 μM
Compound: 1
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
[PMID: 22551630]
CCRF-CEM IC50
250 μM
Compound: 2
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
[PMID: 17371067]
CCRF-CEM IC50
50.8 μM
Compound: betulin
Cytotoxicity against human CCRF-CEM by XTT assay
Cytotoxicity against human CCRF-CEM by XTT assay
[PMID: 20527917]
CHO EC50
> 10 μM
Compound: Betulin
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
[PMID: 19911773]
COS-1 EC50
0 μM
Compound: Betulin
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
[PMID: 19911773]
DLD-1 IC50
> 200 μM
Compound: 2
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
[PMID: 19200744]
DLD-1 IC50
6.6 μM
Compound: 1
Cytotoxicity against human DLD1 cells after 48 hrs
Cytotoxicity against human DLD1 cells after 48 hrs
[PMID: 19115839]
DLD-1 IC50
6.6 μM
Compound: 2
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
[PMID: 19200744]
DLD-1 IC50
6.6 μM
Compound: 2
Cytotoxicity against human DLD1 cells by resazurin reduction test
Cytotoxicity against human DLD1 cells by resazurin reduction test
[PMID: 19285391]
DU-145 GI50
> 10 μg/mL
Compound: Betulin
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
[PMID: 29303263]
DU-145 GI50
> 10 μg/mL
Compound: 1
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
[PMID: 24694263]
DU-145 IC50
136.7 μM
Compound: 11
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
[PMID: 29120172]
DU-145 CC50
161.8 μM
Compound: 11
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
[PMID: 29120172]
ECa-109 cell line IC50
26.64 μM
Compound: 1
Cytotoxicity against human ECA109 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human ECA109 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 28671831]
Epithelial cell IC50
> 20 μM
Compound: betulin
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
[PMID: 18826277]
FaDu EC50
> 30 μM
Compound: BN
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
Fibroblast CC50
7.6 μM
Compound: 1
Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay
Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay
[PMID: 33877845]
H9 EC50
23 μM
Compound: 4
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
[PMID: 8176401]
H9 EC50
23 μM
Compound: 6
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
[PMID: 9804704]
H9 IC50
45 μM
Compound: 4
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
[PMID: 8176401]
HCT-116 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
HCT-8 IC50
> 10 μM
Compound: 23
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
[PMID: 24467317]
HEK293 CC50
> 500 μM
Compound: 11
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
[PMID: 29120172]
HEK293 IC50
> 500 μM
Compound: 11
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
[PMID: 29120172]
HeLa IC50
> 10 μg/mL
Compound: betulin
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
[PMID: 16038541]
HeLa EC50
> 30 μM
Compound: BN
Cytotoxicity against human HeLa cells after 96 hrs by SRB assay
Cytotoxicity against human HeLa cells after 96 hrs by SRB assay
[PMID: 27142753]
HeLa CC50
> 500 μM
Compound: 11
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
[PMID: 29120172]
HeLa IC50
> 500 μM
Compound: 11
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
[PMID: 29120172]
HeLa IC50
12.2 μM
Compound: Betulin
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31708185]
HEp-2 IC50
> 10 μg/mL
Compound: betulin
Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay
Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay
[PMID: 16038541]
HEp-2 CC50
> 500 μM
Compound: 11
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
[PMID: 29120172]
HEp-2 IC50
> 500 μM
Compound: 11
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
[PMID: 29120172]
HepG2 IC50
> 20 μM
Compound: Betulin
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31708185]
HepG2 IC50
10.7 μM
Compound: 1
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 28671831]
HepG2 IC50
17 μM
Compound: 13
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
[PMID: 15730243]
HL-60 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
[PMID: 34352711]
HL-60 IC50
30.94 μM
Compound: 1
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 28671831]
HT-29 IC50
> 10 μM
Compound: 12
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
[PMID: 30057155]
HT-29 IC50
> 10 μM
Compound: 12
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
HT-29 IC50
> 20 μM
Compound: Betulin
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31708185]
HT-29 EC50
> 30 μM
Compound: BN
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
HT-29 EC50
> 30 μM
Compound: BN
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 27142753]
HT-29 EC50
> 30 μM
Compound: Betulin
Cytotoxicity against human HT-29 cells by SRB assay
Cytotoxicity against human HT-29 cells by SRB assay
[PMID: 26007303]
J774 IC50
67.1 μM
Compound: 6
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
[PMID: 17637068]
K562 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
[PMID: 34352711]
K562 IC50
12.89 μM
Compound: 1
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 28671831]
KB IC50
> 10 μg/mL
Compound: betulin
Cytotoxicity against vincristine-sensitive human KB cells after 72 hrs by alamar blue assay
Cytotoxicity against vincristine-sensitive human KB cells after 72 hrs by alamar blue assay
[PMID: 15043435]
KB CC50
> 500 μM
Compound: 11
Cytotoxic activity in human KB cells by sulforhodamine B assay
Cytotoxic activity in human KB cells by sulforhodamine B assay
[PMID: 29120172]
KB IC50
> 500 μM
Compound: 11
Antiproliferative activity in human KB cells by sulforhodamine B assay
Antiproliferative activity in human KB cells by sulforhodamine B assay
[PMID: 29120172]
KM-20L2 GI50
> 10 μg/mL
Compound: Betulin
Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay
Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay
[PMID: 29303263]
KM-20L2 GI50
> 10 μg/mL
Compound: 1
Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay
Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay
[PMID: 24694263]
L02 IC50
26.82 μM
Compound: 1
Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 28671831]
LN-229 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
MCF7 GI50
> 10 μg/mL
Compound: Betulin
Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
[PMID: 29303263]
MCF7 GI50
> 10 μg/mL
Compound: 1
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
[PMID: 24694263]
MCF7 EC50
> 30 μM
Compound: BN
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
MCF7 EC50
> 30 μM
Compound: BN
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 27142753]
MCF7 EC50
> 30 μM
Compound: 2
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 26547057]
MCF7 CC50
> 500 μM
Compound: 11
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
[PMID: 29120172]
MCF7 IC50
> 500 μM
Compound: 11
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
[PMID: 29120172]
MCF7 IC50
19.3 μM
Compound: 1, BE, Betulin
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 26280921]
MCF7 IC50
23.3 μM
Compound: 1
Cytotoxicity against human MCF7 cells after 48 hrs
Cytotoxicity against human MCF7 cells after 48 hrs
[PMID: 19115839]
MCF7 EC50
24.4 μM
Compound: Betulin
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
[PMID: 26007303]
MCF7 IC50
43.88 μM
Compound: 1
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
[PMID: 31158746]
MDA-MB-231 IC50
> 10 μM
Compound: 12
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
MDA-MB-231 CC50
> 500 μM
Compound: 11
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
[PMID: 29120172]
MDA-MB-231 IC50
> 500 μM
Compound: 11
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
[PMID: 29120172]
MDA-MB-231 IC50
24.57 μM
Compound: 6
Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
[PMID: 33359608]
MDA-MB-231 IC50
96.19 μM
Compound: 1
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
[PMID: 31158746]
MDA-MB-435 IC50
> 10 μM
Compound: 12
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
MDCK IC50
> 20 μM
Compound: Betulin
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31708185]
MGC-803 IC50
30.2 μM
Compound: 1, BE, Betulin
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
[PMID: 26280921]
MIA PaCa-2 IC50
95 μM
Compound: 6
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
[PMID: 33359608]
NCI-H460 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
[PMID: 34352711]
NCI-H460 GI50
7.4 μg/mL
Compound: Betulin
Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay
[PMID: 29303263]
NCI-H460 GI50
7.4 μg/mL
Compound: 1
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
[PMID: 24694263]
NIH3T3 EC50
> 30 μM
Compound: BN
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
[PMID: 31718946]
NIH3T3 EC50
> 30 μM
Compound: 2
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 26547057]
OVCAR-3 IC50
> 10 μM
Compound: 12
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
[PMID: 30057155]
PC-3 IC50
17.9 μM
Compound: 1
Cytotoxicity against human PC3 cells after 48 hrs
Cytotoxicity against human PC3 cells after 48 hrs
[PMID: 19115839]
PC-3 IC50
22.4 μM
Compound: 1, BE, Betulin
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
[PMID: 26280921]
SF-268 GI50
> 10 μg/mL
Compound: Betulin
Growth inhibition of human SF268 cells after 48 hrs by SRB assay
Growth inhibition of human SF268 cells after 48 hrs by SRB assay
[PMID: 29303263]
SF-268 GI50
> 10 μg/mL
Compound: 1
Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
[PMID: 24694263]
SiHa CC50
> 500 μM
Compound: 11
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
[PMID: 29120172]
SiHa IC50
> 500 μM
Compound: 11
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
[PMID: 29120172]
T47D IC50
20.72 μM
Compound: 1
Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 72 hrs by WST1 assay
[PMID: 31158746]
Vero IC50
> 10 μg/mL
Compound: betulin
Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay
[PMID: 16038541]
Vero CC50
> 500 μM
Compound: 11
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
[PMID: 29120172]
Vero IC50
> 500 μM
Compound: 11
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
[PMID: 29120172]
Vero IC50
0.9 μM
Compound: Betulin
Antiviral activity against HSV-1 F infected in African green monkey Vero cells after 2 days by plaque reduction assay
Antiviral activity against HSV-1 F infected in African green monkey Vero cells after 2 days by plaque reduction assay
[PMID: 26112446]
Vero CC50
165 μM
Compound: Betulin
Cytotoxicity against African green monkey Vero cells after 2 days by neutral red uptake assay
Cytotoxicity against African green monkey Vero cells after 2 days by neutral red uptake assay
[PMID: 26112446]
Vero IC50
9.4 μM
Compound: Betulin
Antiviral activity against HSV-2 G infected in African green monkey Vero cells after 2 days by plaque reduction assay
Antiviral activity against HSV-2 G infected in African green monkey Vero cells after 2 days by plaque reduction assay
[PMID: 26112446]
WI-38 IC50
1.4 μM
Compound: 13
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
[PMID: 15730243]
WI-38 VA13 IC50
20.3 μM
Compound: 13
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
[PMID: 15730243]
Z-138 IC50
> 100 μM
Compound: BE
Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
[PMID: 34352711]
In Vitro

Betulin (BE) displays a broad spectrum of biological and pharmacological properties, among which the anticancer and chemopreventive activity attract most of the attention. BE has been shown to elicit anticancer properties by inhibiting cancer cells growth. BE has exhibited quite a different range of its antiproliferative activity, depending on cancer cells type, from a weak inhibition of cell proliferation in human erythroleukaemia cell line (K562) to a strong inhibition in human neuroblastoma cells (SK-N-AS), where the effect has been most pronounced. Additionally, BE has also been found to express significant cytotoxicity against primary cancer cells cultures isolated from tumour samples obtained from ovarian, cervical carcinoma, and glioblastoma patients, where the IC50 values have ranged from 2.8 to 3.4 μM, being significantly lower, when compared with established cell lines[1]. The cytotoxic activity of crude birch bark extract and purified betulin and betulinic acid towards human gastric carcinoma (EPG85-257) and human pancreatic carcinoma (EPP85-181) drug-sensitive and drug-resistant (daunorubicin and mitoxantrone) cell lines are compared. Significant differences in sensitivity between cell lines depending on the compound used are shown, suggesting that both betulin and betulinic acid can be considered as a promising leads in the treatment of cancer[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Betulin could improve glucose intolerance and modify basal learning performance. Treatment with betulin significantly restores SOD activity and decreased MDA content in hippocampus. Betulin also markedly reduces the contents of inflammatory cytokines in serum and hippocampus. Furthermore, administration of BE effectively upregulated the expressions of Nrf2, HO-1 and blocked the phosphorylations of IκB, NF-κB. In summary, BE might exhibit protective effect on cognitive decline in STZ-induced diabetic rats through HO-1/Nrf-2/ NF-κB pathway[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

442.72

Formula

C30H50O2

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C=C(C)[C@@H]1CC[C@]2(CO)CC[C@@]3(C)[C@]4(C)CC[C@@]5([H])C(C)(C)[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3([H])[C@]21[H]

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 3.33 mg/mL (7.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2588 mL 11.2938 mL 22.5876 mL
5 mM 0.4518 mL 2.2588 mL 4.5175 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% Saline

    Solubility: ≥ 0.2 mg/mL (0.45 mM); Clear solution

  • Protocol 2

    Add each solvent one by one:  5% DMSO    95% Corn Oil

    Solubility: ≥ 0.2 mg/mL (0.45 mM); Clear solution

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 3 mg/mL (6.78 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

References
Cell Assay
[2]

Chemoresistance is tested using a proliferation assay based on sulphorhodamine B staining. Briefly, 800 cells per well are seeded in triplicate in 96-well plates. After attachment for 24 h, substances are added in dilution series for a 5-day incubation, before SRB staining is performed. Incubation is terminated by replacing the medium with 10% trichloroacetic acid, followed by further incubation at 4°C for 1h. Subsequently, the plates are ished five times with water and stained by adding 100 μL 0.4% SRB in 1% acetic acid for 10 min at room temperature. Ishing the plates five times with 1% acetic acid eliminated unbound dye. After air-drying and re-solubization of the protein bound dye in 10 mM Tris-HCl (pH=8.0), absorbance is read at 562 nm[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Rats: The rats are randomLy divided into five groups (n=10): control group, STZ group, STZ+betulin (20 mg/kg) group, STZ+betulin (40 mg/kg) group. Diabetes is induced by STZ (30 mg/kg, i.p.) dissolved in citrate buffer (pH 4.4, 0.1 M) using 1 mL syringe for 4 weeks, meanwhile the control rats receive an equal volume of citrate buffer. Thereafter, the diabetic rats are treated with betulin (20 mg/kg, 40 mg/kg) for another 4 weeks[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2588 mL 11.2938 mL 22.5876 mL 56.4691 mL
5 mM 0.4518 mL 2.2588 mL 4.5175 mL 11.2938 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Betulin
Cat. No.:
HY-N0083
Quantity:
MCE Japan Authorized Agent: